You are here

Enhanced Canine Performance, Protection and Survivability

Award Information
Agency: Department of Defense
Branch: Special Operations Command
Contract: H92222-18-P-0007
Agency Tracking Number: S172-002-0089
Amount: $148,088.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: SOCOM172-002
Solicitation Number: 2017.2
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2017-11-21
Award End Date (Contract End Date): 2018-05-21
Small Business Information
100 Cummings Center, Suite 438N
Beverly, MA 01915
United States
DUNS: 080189823
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Kim Vandegriff
 (858) 583-1223
 kim.vandegriff@virtechbio.com
Business Contact
 Joseph Tucker
Phone: (508) 627-0485
Email: joe.tucker@virtechbio.com
Research Institution
N/A
Abstract

The goal of this Proposal is treatment of hemorrhage in SOCOM canines using a novel hemoglobin resuscitation fluid with oxygen carrying and plasma expansion properties (VIR-VET, a product of VirTech Bio). VIR-VET is designed to provide immediate hemodynamic stability and oxygenation to injured canines with blood loss. The product has advantages over traditional military fluid therapies: 1) As cell-free hemoglobin, blood donors are not required. 2) It is a colloid that expands intravascular volume with high oxygen carrying capacity. 3) It has high MW to prolong circulating time. Logistical benefits include temperature stability and ease of administration. It is packaged in oxygen-impermeable bags as an iso-osmotic salt solution and administered using standard blood infusion sets so that specialized equipment is not necessary. The Statement of Work includes two protocols to test safety and efficacy in rats with a dose-ranging study of VIR-VET and Lactated Ringers as control. Evaluations will include hemodynamics, blood gases, microvascular visualizations and interstitial oxygen measurements. Aim 1 is to show safety in a 10% top-load infusion model. Aim 2 is to look toward efficacy using more severe exchange transfusion models in which rat blood is isovolemically hemodiluted with either test (VIR-VET) or control solution.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government